• IM Cannabis Corp. (IMCC) has closed the first tranche of its non-brokered private placement
  • Under the first tranche, the company issued 400,000 units at US$1.25 per unit for gross proceeds of US$500,000
  • The company also closed a non-brokered private placement under a separate offering of  1,159,999 units for gross proceeds of US$1,449,999
  • IM Cannabis is an international cannabis company providing products to medical patients and adult-use recreational consumers
  • IM Cannabis Corp. opened trading at C$1.76

IM Cannabis Corp. (IMCC) has closed the first tranche of a non-brokered private placement for gross proceeds of US$500,000.

Under the first tranche of the previously-announced offering, the company issued 400,000 units at US$1.25 per unit. Each unit consists of one common share and one share purchase warrant. Each warrant may be exercised to purchase one additional common share at an exercise price of US$1.50 for a period of 36 months. 

The securities will be issued under the Listed Issuer Financing Exemption Offering and will not be subject to any statutory hold period.

Net proceeds will be used for general working capital purposes.

“Given the market and business dynamics across our regions, capital allocation has become more important than ever,” stated Oren Shuster, Chief Executive Officer of IM Cannabis. “We continue to be strongly focused on generating efficiencies and synergies, bringing all our financial and human capital to support the growth and success of the company.”

The offering is expected to close on or about March 2, 2023.

The company also closed a separate non-brokered private placement of 1,159,999 units for gross proceeds of US$1,449,999.

IM Cannabis is an international cannabis company providing products to medical patients and adult-use recreational consumers. IM Cannabis has operations in Israel, Germany, and Canada.

IM Cannabis Corp. opened trading at C$1.76. 


More From The Market Online
Cannabis Report image of farmed cannabis plants

StockTalk | Cannabis Report: Quarterly report season heats up

Vertically-integrated producer of premium-grade cannabis products, Cannara Biotech Inc. reported gross cannabis revenues before excise taxes...
Cannabis Report across cannabis plants

StockTalk | Cannabis Report: Shake-ups

MediPharm Labs announced that chief executive officer, David Pidduck will step down from his role, effective January...

Buzz on the Bullboards: As Arctic tensions flare, investors eye three news‑making stocks

Global markets opened the week on edge as a fresh rift between Washington and key NATO...

MediPharm Labs announces CEO transition as David Pidduck steps down

MediPharm Labs (TSX:LABS) CEO David Pidduck will step down on January 23, 2026, and will remain on the Board to support the transition.